These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33879168)

  • 1. Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis.
    Sun X; Zhen X; Hu X; Li Y; Gu S; Gu Y; Zhao Z; Yang W; Dong H
    Cost Eff Resour Alloc; 2021 Apr; 19(1):22. PubMed ID: 33879168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of imrecoxib compared with celecoxib for patients with osteoarthritis.
    Sun X; Zhen X; Hu X; Li Y; Gu S; Gu Y; Zhao Z; Yang W; Dong H
    Ann Transl Med; 2021 Apr; 9(7):575. PubMed ID: 33987273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
    Brereton N; Pennington B; Ekelund M; Akehurst R
    J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imrecoxib: Advances in Pharmacology and Therapeutics.
    Wang YH; Zhu LL; Li TL; Zhou Q
    Drug Des Devel Ther; 2024; 18():1711-1725. PubMed ID: 38799798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
    Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
    Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam.
    Tavakoli M
    Pharmacoeconomics; 2003; 21(6):443-54. PubMed ID: 12678570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
    Wielage R; Bansal M; Wilson K; Klein R; Happich M
    Spine (Phila Pa 1976); 2013 May; 38(11):936-46. PubMed ID: 23250234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
    Brereton N; Winn B; Akehurst R
    J Med Econ; 2012; 15(3):465-72. PubMed ID: 22260652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain.
    Capel M; Tornero J; Zamorano JL; Oyagüez I; Casado MÁ; Sánchez-Covisa J; Lanas A
    Reumatol Clin; 2014; 10(4):210-7. PubMed ID: 24380809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers.
    Zuo CZ; Gong Y; Hou XY; Zhang YF; Peng WX; Zhu RH; Zhong DF; Chen XY
    Clin Ther; 2018 Aug; 40(8):1347-1356. PubMed ID: 30017171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis.
    Xie H; Zhang Y; Zhu Z; Wei J; Ainiwaer G; Ge W
    Rheumatol Ther; 2024 Apr; 11(2):269-283. PubMed ID: 38236456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.
    Elías I; Ortega-Joaquín N; de la Cueva P; Del Pozo LJ; Moreno-Ramírez D; Boada A; Aguilar M; Mirada A; Mosquera E; Gibbons C; Oyagüez I
    Actas Dermosifiliogr; 2016; 107(6):498-508. PubMed ID: 27130804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective.
    Wielage RC; Patel AJ; Bansal M; Lee S; Klein RW; Happich M
    Arthritis Care Res (Hoboken); 2014 May; 66(5):702-8. PubMed ID: 24877251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic model of long-term use of celecoxib in patients with osteoarthritis.
    Loyd M; Rublee D; Jacobs P
    BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of imrecoxib in patients with renal insufficiency.
    Pei Q; Xie JL; Huang J; Liu WY; Yang XY; Wang Y; Li W; Tan HY; Zhang H; Yang GP
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1355-1360. PubMed ID: 31243478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac.
    Mladsi D; Ronquest N; Odom D; Miles L; Saag K
    Clin Ther; 2016 Nov; 38(11):2418-2429. PubMed ID: 27793353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.